Keay Nakae
Stock Analyst at Chardan Capital
(1.38)
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
MNPR Monopar Therapeutics | Initiates Coverage On: Buy | 60 | 33.11 | 81.21% | 1 | Jun 23, 2025 | |
DYN Dyne Therapeutics | Maintains: Buy | 50 50 | 10.62 | 370.81% | 12 | Jun 17, 2025 | |
SLN Silence Therapeutics | Maintains: Buy | 35 35 | 6.04 | 479.47% | 12 | Jun 13, 2025 | |
RNA Avidity Biosciences | Maintains: Strong Buy | 65 75 | 29.91 | 150.75% | 17 | Jun 9, 2025 | |
SABS SAB Biotherapeutics | Maintains: Buy | 20 20 | 1.77 | 1029.94% | 15 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 20 20 | 3.22 | 521.12% | 10 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 25 25 | 12.68 | 97.16% | 2 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 14 14 | 5.79 | 141.8% | 18 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 60 60 | 15.96 | 275.94% | 19 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 2 6 | 8.38 | -28.4% | 10 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 5 5 | 0.73 | 584.93% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 300 325 | 325 | 0% | 13 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 20 20 | 1.15 | 1639.13% | 14 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 6 6 | 1.78 | 237.08% | 7 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 5 5 | 3.39 | 47.49% | 12 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 3 3 | 2.41 | 3.73% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 4 4 | 2.02 | 98.02% | 14 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 10 8 | 0.89 | 798.88% | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 7 6 | n/a | n/a | 6 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 7 5 | n/a | n/a | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 5 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 9 | n/a | n/a | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 8 6 | 10.46 | -42.64% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 8 | n/a | n/a | 5 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 50 | n/a | n/a | 4 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 60 20 | n/a | n/a | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 65 55 | 6.74 | 716.02% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 175 125 | n/a | n/a | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 5 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 2 10 | 5.84 | 71.23% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 3 2 | n/a | n/a | 4 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 28 39 | n/a | n/a | 4 | Dec 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 100 88 | 14.46 | 505.12% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 1 13 | 1.03 | 1162.14% | 3 | Feb 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 155 40 | 3.2 | 1150% | 2 | Jun 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Terminates Coverage On: Buy | 3 0 | n/a | n/a | 3 | May 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 65 70 | n/a | n/a | 2 | Mar 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 22500 | n/a | n/a | 1 | Jun 2, 2017 |